API5

Apoptosis inhibitor 5 · Q9BZZ5 · API5 on Sugi Atlas →

0 patent compounds predicted against API5, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to API5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma PHASE4UNKNOWN
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE3COMPLETED
Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma PHASE3UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) PHASE1/PHASE2COMPLETED
Mesalazine Effects in Sporadic Colorectal Adenoma Patients PHASE2COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors PHASE1COMPLETED
Safety Study of Infusion of SGT-53 to Treat Solid Tumors PHASE1COMPLETED
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma PHASE1COMPLETED
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma PHASE1WITHDRAWN
The Effect of TRA-8 on Ovarian Cancer Tissue nanCOMPLETED
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage nanENROLLING_BY_INVITATION
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan nanUNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Impact of CASP3 Gene in Chemoresistance nanNOT_YET_RECRUITING
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF nanNOT_YET_RECRUITING
Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma nanCOMPLETED
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure nanRECRUITING
Autophagy Bladder Cancer nanUNKNOWN
Circulating Markers for Ischemic Heart Disease nanRECRUITING
The Effect of Vitamin E-coated Polysulfone Membrane on Oxidative Stress, Inflammation and Monocytes in Critically Ill Patients in CRRT nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a API5 binder may also engage these)

ProteinNameSimilarity
Q5ZMW3 1.000 Q5ZMW3 →
O35841 1.000 O35841 →
Q5R644 1.000 Q5R644 →
Q7ZY79 0.993 Q7ZY79 →
Q6DDM4 0.993 Q6DDM4 →
PDS5A Sister chromatid cohesion protein PDS5 homolog A 0.978 landscape →
Q5F3U9 0.977 Q5F3U9 →
Q56A27 0.977 Q56A27 →
Q1JU68 0.976 Q1JU68 →
A4L9P7 0.976 A4L9P7 →
Q7TPD0 0.976 Q7TPD0 →
Q5F3V3 0.975 Q5F3V3 →
EIF3A Eukaryotic translation initiation factor 3 subunit A 0.975 landscape →
BZW2 eIF5-mimic protein 1 0.975 landscape →
A0MT11 0.975 A0MT11 →
Q5ZJZ6 0.975 Q5ZJZ6 →
Q5ZKG8 0.975 Q5ZKG8 →
A4GWN3 0.975 A4GWN3 →
Q6A026 0.974 Q6A026 →
Q4VA53 0.974 Q4VA53 →
Q8IWV8 0.974 Q8IWV8 →
A2AT37 0.974 A2AT37 →
A1L1F4 0.973 A1L1F4 →
O00507 0.973 O00507 →
Q5R6J0 0.973 Q5R6J0 →
Q6GQD0 0.973 Q6GQD0 →
Q68E01 0.972 Q68E01 →
USP9X Ubiquitin carboxyl-terminal hydrolase 9X 0.972 landscape →
A1Z3X3 0.972 A1Z3X3 →
Q498H0 0.972 Q498H0 →